Keymed Biosciences Inc. (HKG: 2162)

Market Cap	8.13B
Revenue (ttm)	87.74M
Net Income (ttm)	-798.43M
Shares Out	275.60M
EPS (ttm)	-3.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,909,000
Average Volume	1,365,820
Open	29.60
Previous Close	29.70
Day's Range	29.35 - 31.25
52-Week Range	26.60 - 47.50
Beta	-0.01
RSI	44.89
Earnings Date	Mar 28, 2025

About Keymed Biosciences

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In additio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 927
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2162

Financial Performance

In 2023, Keymed Biosciences's revenue was 354.10 million, an increase of 253.87% compared to the previous year's 100.06 million. Losses were -359.36 million, 16.6% more than in 2022.

Financial numbers in CNY